Peer-reviewedCC BYFrontiers in medicine
Season-adjusted longitudinal changes in serum 25-hydroxyvitamin D during pegylated interferon add-on to ongoing tenofovir alafenamide therapy in chronic hepatitis B: a real-world cohort study
- 1Center of Infectious Diseases, West China Hospital of Sichuan University , ,
Related
- Assessing Renal Outcomes After Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People with HIV: Proteinuria Changes and Limits of Causal Attribution.
- A real-world pharmacovigilance study of FDA adverse event reporting system events for bictegravir/emtricitabine/tenofovir alafenamide
- Bictegravir/emtricitabine/tenofovir alafenamide for HIV: a meta-analysis of efficacy across treatment-naïve and experienced populations and comparative effectiveness versus dolutegravir/lamivudine
- Established Versus Novel Strategies for Hepatitis B Functional Cure: A Cross-Regional Cost-Effectiveness Analysis of Pegylated Interferon and Bepirovirsen Add-on Therapy
- Prevalence of Decisional Regret and Associated Risk Factors in Patients With Hepatitis B Undergoing Pegylated Interferon Alpha Therapy
BibTeX
@article{han2026seasonadjusted,
title = {{Season-adjusted longitudinal changes in serum 25-hydroxyvitamin D during pegylated interferon add-on to ongoing tenofovir alafenamide therapy in chronic hepatitis B: a real-world cohort study}},
author = {Ning Han and Huan Liu and Xia Zhu},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13661473},
note = {CC BY},
}
RIS
TY - JOUR
TI - Season-adjusted longitudinal changes in serum 25-hydroxyvitamin D during pegylated interferon add-on to ongoing tenofovir alafenamide therapy in chronic hepatitis B: a real-world cohort study
AU - Ning Han
AU - Huan Liu
AU - Xia Zhu
PY - 2026
DA - 2026/10/16
JO - Frontiers in medicine
UR - https://europepmc.org/article/PMC/PMC13661473
SN - 2296-858X
ER -